| abstract |
A pharmaceutical Compound comprising a Compound of the formula IB: ** Formula ** or a pharmaceutically acceptable salt, solvate, stereoisomer and / or ester thereof, wherein: R10a and R10b are each independently H or alkyl -C1-4; R12 is H or -CH3; R13 is - (CH2) 0-3CR17R18NR20R21, - (CH2) 0-3CR17R18NR17C (O) NR20R21, - (CH2) 1-3C (O) R22, - (CH2) 1-3S (O) 2R22 or - (CH2) 1-3-R23; R14 and R15 are each independently H, C1-4alkyl or arylalkyl; R17 and R18 are each independently H or C1-3alkyl; R19 is H, C1-4alkyl or arylalkyl; R20 and R21 are each independently H, C1-3alkyl, -C (O) R17 or -S (O) 2R17; or R20 and R21, taken together with the nitrogen atom to which they are attached, form a heterocyclyl ring d. 5. 6 unsubstituted or substituted members containing 1 -2 heteroatoms selected from the group consisting of N and O; R22 is H, C1-3alkyl, -OR19 or -NR20R21; and R23 is an unsubstituted or substituted 6-membered heterocyclyl d-ring containing 1 -2 heteroatoms selected from the group consisting of N and O; wherein said heterocyclyl ring d. 5. 6 unsubstituted or substituted members consisting of R20 and R21 and said heterocyclyl ring d. 5. 6 unsubstituted or substituted members of R23 are each independently unsubstituted or substituted with a C1-2 alkyl, a pharmaceutically acceptable carrier or excipient and atazanavir or a pharmaceutically acceptable salt, solvate or excipient thereof. |